<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title>International Journal of Molecular Sciences</journal-title>
<abbrev-journal-title>Int. J. Mol. Sci.</abbrev-journal-title>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/ijms13077886</article-id>
<article-id pub-id-type="publisher-id">ijms-13-07886</article-id>
<article-categories>
<subj-group>
<subject>Review</subject></subj-group></article-categories>
<title-group>
<article-title>Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Stolfi</surname><given-names>Carmine</given-names></name><xref ref-type="corresp" rid="c1-ijms-13-07886">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>Pallone</surname><given-names>Francesco</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Monteleone</surname><given-names>Giovanni</given-names></name></contrib>
<aff id="af1-ijms-13-07886">Department of Systems Medicine, University of “Tor Vergata”, Via Montpellier 1, Rome 00133, Italy; E-Mails: <email>pallone@uniroma2.it</email> (F.P.); <email>gi.monteleone@med.uniroma2.it</email> (G.M.)</aff></contrib-group>
<author-notes>
<corresp id="c1-ijms-13-07886">
<label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>carmine.stolfi@uniroma2.it</email>; Tel.: +39-06-72596158; Fax: +39-06-72596391.</corresp></author-notes>
<pub-date pub-type="collection">
<year>2012</year></pub-date>
<pub-date pub-type="epub">
<day>25</day>
<month>06</month>
<year>2012</year></pub-date>
<volume>13</volume>
<issue>7</issue>
<fpage>7886</fpage>
<lpage>7901</lpage>
<history>
<date date-type="received">
<day>01</day>
<month>06</month>
<year>2012</year></date>
<date date-type="rev-recd">
<day>18</day>
<month>06</month>
<year>2012</year></date>
<date date-type="accepted">
<day>20</day>
<month>06</month>
<year>2012</year></date></history>
<permissions>
<copyright-statement>© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement>
<copyright-year>2012</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), a member of the TNF superfamily, interacts with its functional death receptors (DRs) and induces apoptosis in a wide range of cancer cell types. Therefore, TRAIL has been considered as an attractive agent for cancer therapy. However, many cancers are resistant to TRAIL-based therapies mainly due to the reduced expression of DRs and/or up-regulation of TRAIL pathway-related anti-apoptotic proteins. Compounds that revert such defects restore the sensitivity of cancer cells to TRAIL, suggesting that combined therapies could help manage neoplastic patients. In this article, we will focus on the TRAIL-sensitizing effects of natural products and synthetic compounds in colorectal cancer (CRC) cells and discuss the molecular mechanisms by which such agents enhance the response of CRC cells to TRAIL.</p></abstract>
<kwd-group>
<kwd>DR4</kwd>
<kwd>DR5</kwd>
<kwd>caspase-8</kwd>
<kwd>p53</kwd>
<kwd>CHOP</kwd>
<kwd>survivin</kwd>
<kwd>extrinsic pathway</kwd>
<kwd>intrinsic pathway</kwd>
<kwd>chemotherapeutics</kwd>
<kwd>natural products</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>1. Introduction</title>
<p>Induction of programmed cell death or apoptosis in tumor cells is a pivotal mechanism for most anti-cancer approaches including chemotherapy, radiation or immunotherapy [<xref ref-type="bibr" rid="b1-ijms-13-07886">1</xref>]. However, conventional anti-cancer strategies are associated with several adverse effects due to their toxicity also in non-transformed cells [<xref ref-type="bibr" rid="b1-ijms-13-07886">1</xref>]. Since its discovery in 1995, tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL/Apo2L), a member of the TNF superfamily [<xref ref-type="bibr" rid="b2-ijms-13-07886">2</xref>], has been involved in cancer biology. TRAIL induces apoptosis in malignant cells both <italic>in vitro</italic> [<xref ref-type="bibr" rid="b3-ijms-13-07886">3</xref>] and in pre-clinical models of cancer [<xref ref-type="bibr" rid="b4-ijms-13-07886">4</xref>,<xref ref-type="bibr" rid="b5-ijms-13-07886">5</xref>]. Moreover, mutations in genes of the TRAIL pathway machinery are associated with human tumorigenesis [<xref ref-type="bibr" rid="b6-ijms-13-07886">6</xref>–<xref ref-type="bibr" rid="b9-ijms-13-07886">9</xref>]. TRAIL shows very little or no toxicity towards normal cells [<xref ref-type="bibr" rid="b4-ijms-13-07886">4</xref>]. The reason why normal cells are resistant to TRAIL-induced apoptosis is not yet known, but there is evidence that non-neoplastic cells express high levels of decoy receptors (DcR)s for TRAIL, which could interfere with TRAIL signaling [<xref ref-type="bibr" rid="b10-ijms-13-07886">10</xref>]. Nonetheless, cells derived from many human cancers, such as colorectal cancer (CRC), are resistant against TRAIL-driven apoptosis due to defects in the TRAIL signaling machinery (e.g., down-regulation and/or impaired functionality of TRAIL receptors, increased level of anti-apoptotic proteins) [<xref ref-type="bibr" rid="b11-ijms-13-07886">11</xref>]. Restoring the susceptibility of CRC cells to TRAIL could thus help improve the ways we manage patients with this neoplasia.</p>
<p>In this article, we discuss the molecular mechanisms by which various natural products and synthetic compounds increase the susceptibility of CRC cells to TRAIL-induced apoptosis.</p></sec>
<sec>
<title>2. TRAIL Signaling Pathway and Mechanisms of TRAIL Resistance</title>
<p>TRAIL is known to bind five different receptors [<xref ref-type="bibr" rid="b12-ijms-13-07886">12</xref>]. Two of these receptors, DR4 (also named TRAIL-R1) and DR5 (also named TRAIL-R2 or KILLER), are coined DRs due to the presence of a cytoplasmic death domain which allows triggering of apoptosis upon TRAIL binding [<xref ref-type="bibr" rid="b13-ijms-13-07886">13</xref>]. DcR1, also termed TRAIL-R3 or TRID, and DcR2 (TRAIL-R4, TRUNDD) are expressed on the cell surface but lack a functional intracellular death domain. Both receptors confer protection against TRAIL-induced apoptosis rather than delivering apoptotic signals [<xref ref-type="bibr" rid="b14-ijms-13-07886">14</xref>] and may be up-regulated by p53 or hypoxia in CRC cells [<xref ref-type="bibr" rid="b15-ijms-13-07886">15</xref>,<xref ref-type="bibr" rid="b16-ijms-13-07886">16</xref>]. The fifth TRAIL-receptor is osteoprotegerin, a secreted, low affinity receptor for TRAIL, suggested to mediate TRAIL resistance even though its physiological relevance is still a matter of debate [<xref ref-type="bibr" rid="b17-ijms-13-07886">17</xref>]. Binding of TRAIL to DR4 and DR5 leads to caspase-8 activation through Fas-associated death domain (FADD) in the death-inducing signaling complex (DISC) [<xref ref-type="bibr" rid="b3-ijms-13-07886">3</xref>]. Activated caspase-8 can induce apoptosis through the so-called extrinsic pathway by directly triggering downstream effector caspases (<italic>i.e</italic>., caspase-3, -6 and -7) [<xref ref-type="bibr" rid="b18-ijms-13-07886">18</xref>]. DRs can also indirectly activate effector caspases through the intrinsic mitochondria-mediated apoptotic pathway [<xref ref-type="bibr" rid="b19-ijms-13-07886">19</xref>]. In this later case, activated caspase-8 cleaves Bid thereby generating truncated Bid (tBid). tBid in turn translocates to the mitochondria where it interacts with Bax and Bak, thereby promoting the release of pro-apoptotic factors, such as cytochrome c and Smac/DIABLO [<xref ref-type="bibr" rid="b19-ijms-13-07886">19</xref>]. Cytochrome c together with Apaf-1 and caspase-9 form a functional apoptosome that results in cleavage and activation of caspase 9 [<xref ref-type="bibr" rid="b20-ijms-13-07886">20</xref>]. Active caspase-9 cleaves and activates executioner caspases (e.g., caspases-3) leading to apoptosis [<xref ref-type="bibr" rid="b19-ijms-13-07886">19</xref>]. In parallel, Smac/DIABLO can bind to and dampen the activity of cellular inhibitor of apoptosis protein (IAP) members [<xref ref-type="bibr" rid="b21-ijms-13-07886">21</xref>] which are powerful caspase inhibitors.</p>
<p>Many cancer cells are resistant to apoptotic signals triggered by TRAIL. The mechanism underlying TRAIL resistance is not fully understood, but it is supposed to rely on defects occurring at various levels in the TRAIL signaling pathway. The first mechanism involves DR expression/function. For example, malignant cells may have diminished expression of DR4 and DR5 due to defective p53 given that p53 directly regulates the transcription of both DRs through specific p53 binding sites [<xref ref-type="bibr" rid="b22-ijms-13-07886">22</xref>]. Down-regulation of DR surface expression could be also due to impaired transport from ribosomes [<xref ref-type="bibr" rid="b23-ijms-13-07886">23</xref>]. Plasma membrane microdomains enriched in cholesterol and glycosphingolipids (<italic>i.e</italic>., lipid rafts) play an important role in clustering or aggregating surface DRs into membrane complexes at specific sites and in the initiation of DR–induced apoptosis [<xref ref-type="bibr" rid="b24-ijms-13-07886">24</xref>,<xref ref-type="bibr" rid="b25-ijms-13-07886">25</xref>]. Therefore defective redistribution/relocalization of DR4 and DR5 in lipid rafts on the outer membrane could contribute further to the weak response of cells to TRAIL [<xref ref-type="bibr" rid="b26-ijms-13-07886">26</xref>]. Finally, impaired DR functionality due either to loss-of-function mutations or epigenetic changes has been documented in neoplastic cells [<xref ref-type="bibr" rid="b27-ijms-13-07886">27</xref>]. A second mechanism relates to defects in the expression/activity of molecules which control DISC function. These include down-regulation, degradation or inactivation of the initiator caspase-8 [<xref ref-type="bibr" rid="b28-ijms-13-07886">28</xref>] as well as perturbations of the physiological level of cellular FLICE-like inhibitory protein (c-FLIP), a molecule that is co-recruited with caspase-8 to the DISC and inhibits caspase-8 release-dependent pro-apoptotic signals [<xref ref-type="bibr" rid="b29-ijms-13-07886">29</xref>,<xref ref-type="bibr" rid="b30-ijms-13-07886">30</xref>]. A low ratio caspase-8/c-FLIP has been described in many CRC cell lines and coupled with increased resistance to TRAIL-induced apoptosis [<xref ref-type="bibr" rid="b31-ijms-13-07886">31</xref>]. Further defects involve intrinsic pathway-related pro-apoptotic proteins (e.g., Bim, Bid, Bax, Bak, PUMA) and molecules able to prevent mitochondria outer-membrane permeabilization and cytochrome c release, such as the anti-apoptotic Bcl-2 family members [e.g., Bcl-2, Bcl-xL and myeloid cell leukemia sequence 1 (Mcl-1)] [<xref ref-type="bibr" rid="b31-ijms-13-07886">31</xref>]. Finally, resistance of cancer cells to TRAIL could be secondary to enhanced expression of IAPs. Indeed, members of the IAP family [e.g., X-linked IAP (XIAP), cellular IAP1 (c-IAP1), c-IAP2, survivin] prevent activation of both caspase-3 and caspase-9 thus inhibiting at the same time both the extrinsic and intrinsic apoptotic pathway [<xref ref-type="bibr" rid="b32-ijms-13-07886">32</xref>]. IAPs, and particularly survivin and XIAP, are up-regulated in CRC [<xref ref-type="bibr" rid="b33-ijms-13-07886">33</xref>,<xref ref-type="bibr" rid="b34-ijms-13-07886">34</xref>] and thought to represent a major hurdle for TRAIL-based therapies in this neoplasia. <xref ref-type="fig" rid="f1-ijms-13-07886">Figure 1</xref> summarizes the TRAIL signaling pathway and the above-mentioned mechanisms of TRAIL resistance.</p></sec>
<sec>
<title>3. TRAIL-Sensitizing Agents in CRC</title>
<p>In recent years numerous chemotherapeutics, natural products and newly synthesized molecules have been screened for their ability to restore TRAIL sensitivity in cancer cells with encouraging results. <xref ref-type="table" rid="t1-ijms-13-07886">Table 1</xref> summarizes the agents reported to overcome TRAIL resistance and synergize with TRAIL in inducing CRC cell death.</p>
<sec>
<title>3.1. Chemotherapeutics–DNA Damage Agents</title>
<p>Chemotherapeutic drugs are widely used in clinical oncology and have been extensively studied as TRAIL sensitizing agents. Enhanced TRAIL DISC formation by several chemotherapeutics allows restoration of TRAIL-induced apoptosis in CRC cells. In particular, cisplatin, VP16 and 5-fluorouracil (5-FU) sensitize HCT-116 and SW480 cells to TRAIL mainly by increasing caspase-8 recruitment and activation at the DISC [<xref ref-type="bibr" rid="b39-ijms-13-07886">39</xref>]. Enhanced FADD and pro-caspase-8 recruitment to the DISC as well as activation of the mitochondria-dependent death pathway underlie the TRAIL-sensitizing effect of cisplatin, 5-FU and doxorubicin in HT-29 cells [<xref ref-type="bibr" rid="b35-ijms-13-07886">35</xref>,<xref ref-type="bibr" rid="b36-ijms-13-07886">36</xref>]. Among the above-mentioned cytotoxic drugs, only 5-FU induces c-FLIP degradation both in HCT-116 [<xref ref-type="bibr" rid="b37-ijms-13-07886">37</xref>,<xref ref-type="bibr" rid="b39-ijms-13-07886">39</xref>] and HT-29 cells [<xref ref-type="bibr" rid="b36-ijms-13-07886">36</xref>] thus contributing to TRAIL sensitization. Additionally, a recent paper indicated that 5-FU sensitizes HCT-116 cells to TRAIL through the induction of DR4 [<xref ref-type="bibr" rid="b38-ijms-13-07886">38</xref>]. Knock-down experiments showed that 5-FU requires both p53-dependent and -independent mechanisms to efficiently trigger apoptosis as well as a functional FADD/caspase-8/Bid axis [<xref ref-type="bibr" rid="b38-ijms-13-07886">38</xref>]. Otherwise, the specific cyclo-oxygenase-2 inhibitor DuP-697 overcomes TRAIL resistance in HT-29 cells by inducing DR5 clustering at the cell surface and the redistribution of the DISC components (<italic>i.e</italic>., DR5, FADD, and pro-caspase-8) in peculiar lipid rafts called caveolae [<xref ref-type="bibr" rid="b25-ijms-13-07886">25</xref>]. TRAIL also synergizes with irinotecan (CPT-11), an analog of the DNA topoisomerase I inhibitor camptothecin, in inducing apoptosis in HCT-116 cells [<xref ref-type="bibr" rid="b40-ijms-13-07886">40</xref>]. This later event associates with DR4 and DR5 up-regulation and enhanced degradation of p21, a negative regulator of the apoptotic process. Semisynthetic retinoid fenretinide promotes DR5 up-regulation through the endoplasmic reticulum (ER) stress-related CAAT/enhancer-binding protein homologous protein (CHOP) thus sensitizing CRC cells to TRAIL-driven apoptosis [<xref ref-type="bibr" rid="b41-ijms-13-07886">41</xref>]. More recently, lapatinib, a dual inhibitor of EGFR and HER2, was reported to increase TRAIL-induced cell death in CRC cells by promoting JNK/c-Jun-driven DR over-expression [<xref ref-type="bibr" rid="b42-ijms-13-07886">42</xref>]. Modulation of molecules involved in the intrinsic/mitochondrial pathway accounts for the sensitization of TRAIL resistant CRC cells to sunitinib, a tyrosine kinase inhibitor, and oxaliplatin, a third-generation platinum agent [<xref ref-type="bibr" rid="b43-ijms-13-07886">43</xref>,<xref ref-type="bibr" rid="b44-ijms-13-07886">44</xref>]. In particular, sunitinib decreases the expression of the anti-apoptotic proteins Mcl-1 and XIAP [<xref ref-type="bibr" rid="b43-ijms-13-07886">43</xref>] while the oxaliplatin-mediated TRAIL sensitization increases phosphorylation of Bcl-xL, thus reducing the anti-apoptotic activity of this protein [<xref ref-type="bibr" rid="b44-ijms-13-07886">44</xref>]. However, it is noteworthy to underline that CRC cells harboring functional p53 (e.g., HCT-116) fail to trigger apoptosis upon oxaliplatin and TRAIL treatments due to a strong p53-dependent, oxaliplatin-mediated, up-regulation of DcR1 [<xref ref-type="bibr" rid="b75-ijms-13-07886">75</xref>].</p></sec>
<sec>
<title>3.2. Natural Products</title>
<p>Since chemotherapeutic drugs lead to DNA damage in cells, combination treatment of TRAIL with these cytotoxic agents, even at lower doses than those used in conventional chemotherapy, can result in severe side effects [<xref ref-type="bibr" rid="b76-ijms-13-07886">76</xref>]. Therefore in the last decade, numerous researchers have focused attention on natural products, which exhibit TRAIL sensitizing effects at concentrations easy to obtain and which appear to be safe [<xref ref-type="bibr" rid="b77-ijms-13-07886">77</xref>].</p>
<sec>
<title>3.2.1. Polyphenols and Related Compounds</title>
<p>Among natural products, polyphenols, and in particular the subgroup of flavonoids, constitute the major category of molecules used in combination with TRAIL in CRC cells. Food polyphenols sensitize CRC cells to TRAIL-driven cell death mainly by increasing the expression of DR5 and to a lesser extent DR4. One such compound is apigenin, a flavonoid widely distributed in many fruits and vegetables. Apigenin increases DR5 expression and synergistically acts with TRAIL in inducing DLD-1 cell death [<xref ref-type="bibr" rid="b45-ijms-13-07886">45</xref>]. DR5 up-regulation also accounts for the TRAIL-sensitizing effect of both baicalein and isoliquiritigenin in SW480 and HT-29 cells, respectively [<xref ref-type="bibr" rid="b46-ijms-13-07886">46</xref>,<xref ref-type="bibr" rid="b47-ijms-13-07886">47</xref>]. Kaempferol, a flavonoid isolated from many plant sources (e.g., tea, broccoli, propolis, grapefruit), also shows TRAIL sensitizing effect in SW480 cells. Kaempferol up-regulates the expression of both DR4 and DR5 but knock-down of DR5 and not DR4 by siRNA effectively abrogates apoptosis induced by the combined treatment of this compound with TRAIL [<xref ref-type="bibr" rid="b48-ijms-13-07886">48</xref>]. DR modulation partly underlies the TRAIL sensitizing effect of quercetin and wogonin [<xref ref-type="bibr" rid="b49-ijms-13-07886">49</xref>,<xref ref-type="bibr" rid="b50-ijms-13-07886">50</xref>]. Quercetin, a flavonoid found in vegetables, fruits and tea, aggregates DRs into lipid rafts thus facilitating the DISC formation without increasing DR expression at the cell surface [<xref ref-type="bibr" rid="b49-ijms-13-07886">49</xref>]. Wogonin, an active ingredient of Chinese herb medicine <italic>Scutellaria baicalensis</italic>, up-regulates DR5 and decreases c-FLIP expression in HT-29 cells [<xref ref-type="bibr" rid="b50-ijms-13-07886">50</xref>]. The TRAIL-sensitizing properties of other tested polyphenols are associated with modulation of different intracellular pro- and anti-apoptotic proteins. For example, cycloartenyl ferulate, a phenolic compound present in γ-oryzanol (a component of the rice bran oil), up-regulates DRs and increases caspase-8 activation as well as Bid cleavage leading to mitochondrial pathway activation in both SW480 and SW620 cells [<xref ref-type="bibr" rid="b51-ijms-13-07886">51</xref>]. In the same cells, the flavonolignan silibinin used in combination with TRAIL synergistically induces cell death through both a p53-independent DR5 up-regulation and down-regulation of Mcl-1 and XIAP [<xref ref-type="bibr" rid="b52-ijms-13-07886">52</xref>]. Another polyphenol recently reported to have TRAIL sensitizing properties in CRC cells is gossypol. Gossypol is derived from cottonseed oil and commonly designated as a BH3 mimetic due to its ability to bind the BH3 binding pockets of Bcl-2 and Bcl-xL thus inhibiting their function [<xref ref-type="bibr" rid="b78-ijms-13-07886">78</xref>]. Beside the down-regulation of anti-apoptotic proteins involved in TRAIL resistance (e.g., Bcl-2, Bcl-xL, survivin), this molecule potentiates TRAIL-driven apoptosis in HCT-116 cells by increasing DR5 expression through the ROS-mediated induction of CHOP [<xref ref-type="bibr" rid="b53-ijms-13-07886">53</xref>]. In the same cells, the ROS-CHOP-mediated up-regulation of DR4 and DR5 is needed for TRAIL sensitization by cardamonin. The potentiation of TRAIL-induced apoptosis by this chalcone also correlates with DcR1 down-regulation and modulation of both pro-apoptotic (<italic>i.e</italic>., Bax) and pro-survival (e.g., Bcl-2, c-IAP1) intracellular proteins [<xref ref-type="bibr" rid="b54-ijms-13-07886">54</xref>].</p></sec>
<sec>
<title>3.2.2. Terpenoids</title>
<p>Terpenoids are one of the largest families of natural products. Terpenoids contained in many plants, and in particular the subclasses of monoterpenes, diterpenes and tetraterpenes (including carotenoids), play a role in traditional herbal medicine and are currently under investigation for their antitumor activities [<xref ref-type="bibr" rid="b79-ijms-13-07886">79</xref>,<xref ref-type="bibr" rid="b80-ijms-13-07886">80</xref>]. Zerumbone, a sesquiterpene isolated from the rhizome of a tropical ginger, shows anticancer activity against different tumor cell types but very little or no cytotoxic effect on normal human endothelial cells and dermal fibroblasts [<xref ref-type="bibr" rid="b81-ijms-13-07886">81</xref>]. In HCT-116 cells, which possess a functional p53, treatment with zerumbone generates ROS and subsequently activates the MAPK ERK1/2 leading to DR4/DR5 induction and TRAIL sensitization [<xref ref-type="bibr" rid="b55-ijms-13-07886">55</xref>]. Interestingly, zerumbone-mediated DR up-regulation as well as the increased TRAIL-induced apoptosis is abolished by ROS scavenging compounds thus suggesting a key role of free radicals in these processes. Additionally, zerumbone markedly down-regulates the expression of c-FLIP without affecting other anti-apoptotic proteins (<italic>i.e</italic>., Bcl-2, Bcl-xL, XIAP, survivin) [<xref ref-type="bibr" rid="b55-ijms-13-07886">55</xref>]. However, zerumbone shows no sensitizing effect on HT-29 cells that express mutant p53 [<xref ref-type="bibr" rid="b55-ijms-13-07886">55</xref>]. An increased susceptibility to TRAIL-induced apoptosis is observed in both HCT-116 and HT-29 cells when treated with nimbolide, a tetranortriterpenoid isolated from the leaves and flowers of the tree <italic>Azadirachta indica</italic> [<xref ref-type="bibr" rid="b56-ijms-13-07886">56</xref>]. Several mechanisms are proposed for this effect. First, nimbolide up-regulates the expression of DRs through ROS production and MAPK pathway activation in a p53-independent fashion. This up-regulation is due to the increase of both transcription and protein stability and is critical for the TRAIL sensitization by this compound. Indeed, knock-down of DRs, and in particular of DR5, significantly hampers the TRAIL-sensitizing effect of nimbolide. Second, nimbolide up-regulates Bax and potentiates the intrinsic pathway of apoptosis. Finally, nimbolide down-regulates the expression of critical anti-apoptotic proteins (<italic>i.e</italic>., c-FLIP, Bcl-2, Bcl-xL, c-IAP1, c-IAP2, survivin and XIAP) [<xref ref-type="bibr" rid="b56-ijms-13-07886">56</xref>]. TRAIL-sensitizing properties are also reported for halocynthiaxanthin, a dietary carotenoid contained in oysters and sea squirts, in DLD-1 and HT-29 cells. This effect is associated with DR5 up-regulation further confirming the key role of this DR in the TRAIL apoptotic pathway [<xref ref-type="bibr" rid="b57-ijms-13-07886">57</xref>].</p></sec>
<sec>
<title>3.2.3. Other Natural Products</title>
<p>TRAIL-sensitizing effects in CRC cells are also reported for other natural products not belonging either to polyphenols or terpenoids, such as vitamin-related compounds. Among these compounds γ-Tocotrienol (γ-T3), an unsaturated tocopherol found in palm oil, rice bran, barley, and wheat germ, enhances TRAIL-induced apoptosis in HCT-116 cells through ERK1/2-driven ROS-dependent DR4/DR5 up-regulation [<xref ref-type="bibr" rid="b58-ijms-13-07886">58</xref>]. Despite p53 not being activated by γ-T3, it is required in the DR up-regulation process as evidenced by the failure of γ-T3 to induce DRs both in p53 knockout HCT-116 cells and in the p53 mutated HT-29 cells [<xref ref-type="bibr" rid="b58-ijms-13-07886">58</xref>]. A different mechanism, independent of the modulation of CHOP, p53, Bax and mitogen-activated protein kinases (MAPK), underlies both DR4 and DR5 up-regulation in CRC cells by garcinol, a compound derived from the dried rind of the fruit <italic>Garcinia indica</italic>. Moreover, garcinol diminishes expression of c-FLIP, Bcl-2, survivin and XIAP [<xref ref-type="bibr" rid="b59-ijms-13-07886">59</xref>]. The down-regulation of anti-apoptotic proteins also account for the sensitization of CRC cells to TRAIL by combretastatin A-4 and the plant stress hormone methyl jasmonate [<xref ref-type="bibr" rid="b60-ijms-13-07886">60</xref>,<xref ref-type="bibr" rid="b61-ijms-13-07886">61</xref>]. Combined treatment of HT-29 cells with TRAIL and the polyunsaturated fatty acid docosahexaenoic acid (DHA) markedly increases cell death compared to the agents used alone [<xref ref-type="bibr" rid="b62-ijms-13-07886">62</xref>]. On the molecular level, DHA dose-dependently induces ROS production, enhances caspase-8 activation and the formation of tBid [<xref ref-type="bibr" rid="b62-ijms-13-07886">62</xref>]. HT-29 cells are sensitized to TRAIL-induced cell death also when exposed to diosgenin, a steroid saponin present in fenugreek (<italic>Trigonella foenum graecum</italic>) and other plants, through the increase of DR5 expression [<xref ref-type="bibr" rid="b63-ijms-13-07886">63</xref>]. Zhang and colleagues demonstrated that the combination of TRAIL and the vitamin A-related compound all-<italic>trans</italic>-retinyl acetate (RAc) restores apoptosis in APC-deficient premalignant cells <italic>in vivo</italic> without affecting normal cells [<xref ref-type="bibr" rid="b64-ijms-13-07886">64</xref>]. A similar effect was observed <italic>in vitro</italic> as RAc sensitizes human colon epithelial cells (NCM356) with altered APC function to TRAIL. Specifically, in these cells, RAc-mediated TRAIL sensitization is associated with DR up-regulation and suppression of both DcR1 and DcR2 thus leading to enhanced caspase-8 activation [<xref ref-type="bibr" rid="b64-ijms-13-07886">64</xref>].</p></sec></sec>
<sec>
<title>3.3. Other TRAIL-Sensitizing Agents</title>
<p>Other TRAIL-sensitizing molecules discussed in this article include proteasome inhibitors, ER stress inducers and molecules controlling p53, AMP-activated protein kinase, protein kinase C and the molecular chaperone Hsp90.</p>
<sec>
<title>3.3.1. Proteasome Inhibitors</title>
<p>Inhibition of the proteasome, a multicatalytic enzyme complex that recognizes and degrades poly-ubiquitinated proteins, has been proposed as a possible therapeutic strategy to manage human malignancies [<xref ref-type="bibr" rid="b82-ijms-13-07886">82</xref>]. In this context, the proteasome inhibitor MG132 cooperates with TRAIL in inducing HCT-116 apoptosis through DR5 up-regulation [<xref ref-type="bibr" rid="b65-ijms-13-07886">65</xref>]. Another proteasome inhibitor, PS-341, synergizes with TRAIL to enhance HCT-116 and HC4 cell death through DR up-regulation and the following activation of both extrinsic and intrinsic apoptotic pathways [<xref ref-type="bibr" rid="b66-ijms-13-07886">66</xref>].</p></sec>
<sec>
<title>3.3.2. ER Stress Inducers</title>
<p>Disruption of ER homeostasis due to various stress conditions leads to accumulation and aggregation of unfolded and/or misfolded proteins in the lumen of this organelle and to activation of an ER stress response termed unfolded protein response [<xref ref-type="bibr" rid="b83-ijms-13-07886">83</xref>]. A large body of evidence indicates that ER stress inducing agents exert antitumor properties [<xref ref-type="bibr" rid="b84-ijms-13-07886">84</xref>]. 15-Deoxy-delta (12,14)-prostaglandin J2 (15dPGJ2), a known ER stress inducer, increases DR5 expression thus sensitizing HCT-116 cells to TRAIL-induced apoptosis. DR5 up-regulation by 15dPGJ(2) is independent of PPAR-γ and p53 but relies on ROS-mediated CHOP induction [<xref ref-type="bibr" rid="b67-ijms-13-07886">67</xref>]. Likewise, ROS and CHOP are critical for dibenzylideneacetone (DBA) to sensitize HCT-116 to TRAIL through DR4 and DR5 induction and down-regulation of anti-apoptotic proteins [<xref ref-type="bibr" rid="b68-ijms-13-07886">68</xref>]. Moreover, DcR2 but not DcR1 is decreased by DBA probably contributing to TRAIL sensitization [<xref ref-type="bibr" rid="b68-ijms-13-07886">68</xref>]. ER stress is also one of the mechanisms by which 2-Methoxy-5-Amino-N-Hydroxybenzamide (termed 2–14), a derivative of mesalamine, restores the susceptibility of CRC cells to TRAIL [<xref ref-type="bibr" rid="b69-ijms-13-07886">69</xref>]. We have also shown that 2–14 inhibits CRC cell growth both <italic>in vitro</italic> and <italic>in vivo</italic> without affecting the proliferation of normal colonic cells, intraepithelial lymphocytes and fibroblasts [<xref ref-type="bibr" rid="b85-ijms-13-07886">85</xref>]. The 2–14-mediated TRAIL sensitization is seen in the p53-mutant DLD-1 and HT-29 cells and this phenomenon is in part dependent on ERK1/2-driven CHOP-mediated DR5 up-regulation [<xref ref-type="bibr" rid="b69-ijms-13-07886">69</xref>]. Additionally, 2–14 promotes the proteasome-mediated degradation of survivin, a major hurdle to TRAIL signaling in these CRC cell lines [<xref ref-type="bibr" rid="b69-ijms-13-07886">69</xref>]. Both CHOP-mediated DR5 increase and survivin down-regulation are also the major mechanisms by which dipyridamole, a thromboxane synthase inhibitor widely used as an antiplatelet, sensitizes SW480 cells to TRAIL [<xref ref-type="bibr" rid="b70-ijms-13-07886">70</xref>].</p></sec>
<sec>
<title>3.3.3. Molecules Controlling p53, AMP-Activated Protein Kinase, Protein Kinase C and the Molecular Chaperone Hsp90</title>
<p>p53 activation can contribute to sensitize tumor cells to TRAIL-induced apoptosis [<xref ref-type="bibr" rid="b86-ijms-13-07886">86</xref>]. Nutlin-3, a cis-imidazoline derivative, interferes with Mdm2-mediated p53 degradation with the downstream effect of promoting p53-dependent up-regulation of DR5 and enhancing HCT-116 susceptibility to TRAIL. The pro-apoptotic effect of nutlin-3 is also mediated by Bcl-2 and XIAP down-regulation [<xref ref-type="bibr" rid="b71-ijms-13-07886">71</xref>]. A p53-dependent TRAIL sensitization is also reported in HCT-116 cells treated with 5-Aminoimidazole-4-carboxamide riboside (AICAR), an activator of AMP-activated protein kinase [<xref ref-type="bibr" rid="b72-ijms-13-07886">72</xref>]. Co-treatment of these cells with AICAR and TRAIL reduces Bcl-2 expression and increases Bid cleavage thus potentiating the intrinsic mitochondrial pathway [<xref ref-type="bibr" rid="b72-ijms-13-07886">72</xref>]. Furthermore, rottlerin and 17-allylamino-17-demethoxygeldanamycin (17-AAG), known to inhibit the protein kinase C and the molecular chaperone Hsp90 respectively, are effective in overcoming TRAIL resistance in HT-29 and RKO cells. This is achieved via direct effects at the level of the mitochondria and by reducing the expression of IAPs, and in particular XIAP [<xref ref-type="bibr" rid="b73-ijms-13-07886">73</xref>,<xref ref-type="bibr" rid="b74-ijms-13-07886">74</xref>].</p></sec></sec></sec>
<sec sec-type="conclusions">
<title>4. Conclusions</title>
<p>Accumulating evidence indicates TRAIL is a promising anti-cancer agent due to its ability to selectively induce apoptosis in transformed cells. However, cancer cells including CRC cells often develop resistance to TRAIL-induced apoptosis and this issue has strongly limited the use of TRAIL-based therapies. Chemotherapeutic drugs are reported to overcome resistance of CRC cells to TRAIL but unfortunately their wide use is limited by the risk of side-effects. Therefore, the validation of effective TRAIL-sensitizing agents which exhibit diminished toxicity is worth pursuing. Several natural and synthetic compounds, which revert various cellular defects contributing to TRAIL resistance, have already been tested with success in CRC cell systems. An important issue relates to the choice of which compound should be used. Since resistance of CRC cells to TRAIL can rely on the presence of multiple defects, we can speculate that compounds that target more pathways simultaneously may have higher potential for anticancer therapy. It would be also useful to better characterize such defects in single patients in order to personalize TRAIL-based therapy. Another concern deals with compounds which increase p53 expression. Indeed, up-regulation of DcRs by p53 may result in a significantly delay of TRAIL-induced killing thus limiting the use of such agents in CRC tumors bearing functional p53. Additionally, hypoxic conditions, easily found in solid tumors, may render CRC cells resistant to some therapeutic agents and attenuate TRAIL-induced cell death. All these drawbacks should be taken into account before designing combined therapies involving TRAIL. Further experimentation is however needed to confirm the <italic>in vitro</italic> data in pre-clinical models of CRC and ascertain the profile of safety and tolerability of such compounds.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This work received support from the “Fondazione Umberto di Mario ONLUS”, Rome, AIRC (IG-9148 to GM and MFAG-12108 to CS), and Giuliani SpA, Milan, Italy.</p></ack>
<fn-group><fn id="fn1-ijms-13-07886">
<p><bold>Conflict of Interest</bold></p>
<p>The authors declare no conflict of interest.</p></fn></fn-group>
<ref-list>
<title>References</title>
<ref id="b1-ijms-13-07886"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>R.W.</given-names></name><name><surname>Ruefli</surname><given-names>A.A.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>Apoptosis: A link between cancer genetics and chemotherapy</article-title><source>Cell</source><year>2002</year><volume>108</volume><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00625-6</pub-id><pub-id pub-id-type="pmid">11832206</pub-id></citation></ref>
<ref id="b2-ijms-13-07886"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>S.R.</given-names></name><name><surname>Schooley</surname><given-names>K.</given-names></name><name><surname>Smolak</surname><given-names>P.J.</given-names></name><name><surname>Din</surname><given-names>W.S.</given-names></name><name><surname>Huang</surname><given-names>C.P.</given-names></name><name><surname>Nicholl</surname><given-names>J.K.</given-names></name><name><surname>Sutherland</surname><given-names>G.R.</given-names></name><name><surname>Smith</surname><given-names>T.D.</given-names></name><name><surname>Rauch</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Identification and characterization of a new member of the tnf family that induces apoptosis</article-title><source>Immunity</source><year>1995</year><volume>3</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(95)90057-8</pub-id><pub-id pub-id-type="pmid">8777713</pub-id></citation></ref>
<ref id="b3-ijms-13-07886"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almasan</surname><given-names>A.</given-names></name><name><surname>Ashkenazi</surname><given-names>A.</given-names></name></person-group><article-title>Apo2l/trail: Apoptosis signaling, biology, and potential for cancer therapy</article-title><source>Cytokine Growth Factor Rev</source><year>2003</year><volume>14</volume><fpage>337</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(03)00029-7</pub-id><pub-id pub-id-type="pmid">12787570</pub-id></citation></ref>
<ref id="b4-ijms-13-07886"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A.</given-names></name><name><surname>Pai</surname><given-names>R.C.</given-names></name><name><surname>Fong</surname><given-names>S.</given-names></name><name><surname>Leung</surname><given-names>S.</given-names></name><name><surname>Lawrence</surname><given-names>D.A.</given-names></name><name><surname>Marsters</surname><given-names>S.A.</given-names></name><name><surname>Blackie</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>McMurtrey</surname><given-names>A.E.</given-names></name><name><surname>Hebert</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety and antitumor activity of recombinant soluble apo2 ligand</article-title><source>J. Clin. Invest</source><year>1999</year><volume>104</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1172/JCI6926</pub-id><pub-id pub-id-type="pmid">10411544</pub-id></citation></ref>
<ref id="b5-ijms-13-07886"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walczak</surname><given-names>H.</given-names></name><name><surname>Miller</surname><given-names>R.E.</given-names></name><name><surname>Ariail</surname><given-names>K.</given-names></name><name><surname>Gliniak</surname><given-names>B.</given-names></name><name><surname>Griffith</surname><given-names>T.S.</given-names></name><name><surname>Kubin</surname><given-names>M.</given-names></name><name><surname>Chin</surname><given-names>W.</given-names></name><name><surname>Jones</surname><given-names>J.</given-names></name><name><surname>Woodward</surname><given-names>A.</given-names></name><name><surname>Le</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <italic>in vivo</italic></article-title><source>Nat. Med</source><year>1999</year><volume>5</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/5517</pub-id><pub-id pub-id-type="pmid">9930862</pub-id></citation></ref>
<ref id="b6-ijms-13-07886"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopkins-Donaldson</surname><given-names>S.</given-names></name><name><surname>Bodmer</surname><given-names>J.L.</given-names></name><name><surname>Bourloud</surname><given-names>K.B.</given-names></name><name><surname>Brognara</surname><given-names>C.B.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>N.</given-names></name></person-group><article-title>Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4315</fpage><lpage>4319</lpage><pub-id pub-id-type="pmid">10969767</pub-id></citation></ref>
<ref id="b7-ijms-13-07886"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Shin</surname><given-names>M.S.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>H.K.</given-names></name><name><surname>Park</surname><given-names>W.S.</given-names></name><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>S.Y.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Oh</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Somatic mutations of trail-receptor 1 and trail-receptor 2 genes in non-hodgkin’s lymphoma</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204103</pub-id><pub-id pub-id-type="pmid">11313970</pub-id></citation></ref>
<ref id="b8-ijms-13-07886"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Shin</surname><given-names>M.S.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>H.K.</given-names></name><name><surname>Park</surname><given-names>W.S.</given-names></name><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>S.Y.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Oh</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Alterations of the dr5/trail receptor 2 gene in non-small cell lung cancers</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>5683</fpage><lpage>5686</lpage><pub-id pub-id-type="pmid">10582684</pub-id></citation></ref>
<ref id="b9-ijms-13-07886"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>M.J.</given-names></name><name><surname>Virmani</surname><given-names>A.K.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Aplenc</surname><given-names>R.</given-names></name><name><surname>Harper</surname><given-names>J.C.</given-names></name><name><surname>Powell</surname><given-names>S.M.</given-names></name><name><surname>Rebbeck</surname><given-names>T.R.</given-names></name><name><surname>Sidransky</surname><given-names>D.</given-names></name><name><surname>Gazdar</surname><given-names>A.F.</given-names></name><name><surname>El-Deiry</surname><given-names>W.S.</given-names></name></person-group><article-title>Nucleotide substitution in the ectodomain of trail receptor dr4 is associated with lung cancer and head and neck cancer</article-title><source>Clin. Cancer Res</source><year>2001</year><volume>7</volume><fpage>1688</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">11410508</pub-id></citation></ref>
<ref id="b10-ijms-13-07886"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strater</surname><given-names>J.</given-names></name><name><surname>Hinz</surname><given-names>U.</given-names></name><name><surname>Walczak</surname><given-names>H.</given-names></name><name><surname>Mechtersheimer</surname><given-names>G.</given-names></name><name><surname>Koretz</surname><given-names>K.</given-names></name><name><surname>Herfarth</surname><given-names>C.</given-names></name><name><surname>Moller</surname><given-names>P.</given-names></name><name><surname>Lehnert</surname><given-names>T.</given-names></name></person-group><article-title>Expression of trail and trail receptors in colon carcinoma: Trail-r1 is an independent prognostic parameter</article-title><source>Clin. Cancer Res</source><year>2002</year><volume>8</volume><fpage>3734</fpage><lpage>3740</lpage><pub-id pub-id-type="pmid">12473583</pub-id></citation></ref>
<ref id="b11-ijms-13-07886"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fang</surname><given-names>B.</given-names></name></person-group><article-title>Mechanisms of resistance to trail-induced apoptosis in cancer</article-title><source>Cancer Gene Ther</source><year>2005</year><volume>12</volume><fpage>228</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700792</pub-id><pub-id pub-id-type="pmid">15550937</pub-id></citation></ref>
<ref id="b12-ijms-13-07886"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeBlanc</surname><given-names>H.N.</given-names></name><name><surname>Ashkenazi</surname><given-names>A.</given-names></name></person-group><article-title>Apo2l/trail and its death and decoy receptors</article-title><source>Cell Death Differ</source><year>2003</year><volume>10</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401187</pub-id><pub-id pub-id-type="pmid">12655296</pub-id></citation></ref>
<ref id="b13-ijms-13-07886"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlo-Stella</surname><given-names>C.</given-names></name><name><surname>Lavazza</surname><given-names>C.</given-names></name><name><surname>Locatelli</surname><given-names>A.</given-names></name><name><surname>Vigano</surname><given-names>L.</given-names></name><name><surname>Gianni</surname><given-names>A.M.</given-names></name><name><surname>Gianni</surname><given-names>L.</given-names></name></person-group><article-title>Targeting trail agonistic receptors for cancer therapy</article-title><source>Clin. Cancer Res</source><year>2007</year><volume>13</volume><fpage>2313</fpage><lpage>2317</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2774</pub-id><pub-id pub-id-type="pmid">17438088</pub-id></citation></ref>
<ref id="b14-ijms-13-07886"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>J.P.</given-names></name><name><surname>Marsters</surname><given-names>S.A.</given-names></name><name><surname>Pitti</surname><given-names>R.M.</given-names></name><name><surname>Gurney</surname><given-names>A.</given-names></name><name><surname>Skubatch</surname><given-names>M.</given-names></name><name><surname>Baldwin</surname><given-names>D.</given-names></name><name><surname>Ramakrishnan</surname><given-names>L.</given-names></name><name><surname>Gray</surname><given-names>C.L.</given-names></name><name><surname>Baker</surname><given-names>K.</given-names></name><name><surname>Wood</surname><given-names>W.I.</given-names></name><etal/></person-group><article-title>Control of trail-induced apoptosis by a family of signaling and decoy receptors</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>818</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1126/science.277.5327.818</pub-id><pub-id pub-id-type="pmid">9242611</pub-id></citation></ref>
<ref id="b15-ijms-13-07886"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>G.T.</given-names></name><name><surname>Wu</surname><given-names>C.W.</given-names></name><name><surname>Lin</surname><given-names>W.W.</given-names></name></person-group><article-title>Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism</article-title><source>Biochem. Biophys. Res. Commun</source><year>2010</year><volume>391</volume><fpage>1274</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.12.058</pub-id><pub-id pub-id-type="pmid">20018172</pub-id></citation></ref>
<ref id="b16-ijms-13-07886"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>R.D.</given-names></name><name><surname>McDonald</surname><given-names>E.R.</given-names><suffix>3rd</suffix></name><name><surname>Sheikh</surname><given-names>M.S.</given-names></name><name><surname>Fornace</surname><given-names>A.J.</given-names><suffix>Jr.</suffix></name><name><surname>El-Deiry</surname><given-names>W.S.</given-names></name></person-group><article-title>The trail decoy receptor trundd (dcr2, trail-r4) is induced by adenovirus-p53 overexpression and can delay trail-, p53-, and killer/dr5-dependent colon cancer apoptosis</article-title><source>Mol. Ther</source><year>2000</year><volume>1</volume><fpage>130</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1006/mthe.2000.0025</pub-id><pub-id pub-id-type="pmid">10933923</pub-id></citation></ref>
<ref id="b17-ijms-13-07886"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Toni</surname><given-names>E.N.</given-names></name><name><surname>Thieme</surname><given-names>S.E.</given-names></name><name><surname>Herbst</surname><given-names>A.</given-names></name><name><surname>Behrens</surname><given-names>A.</given-names></name><name><surname>Stieber</surname><given-names>P.</given-names></name><name><surname>Jung</surname><given-names>A.</given-names></name><name><surname>Blum</surname><given-names>H.</given-names></name><name><surname>Goke</surname><given-names>B.</given-names></name><name><surname>Kolligs</surname><given-names>F.T.</given-names></name></person-group><article-title>Opg is regulated by beta-catenin and mediates resistance to trail-induced apoptosis in colon cancer</article-title><source>Clin. Cancer Res</source><year>2008</year><volume>14</volume><fpage>4713</fpage><lpage>4718</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5019</pub-id><pub-id pub-id-type="pmid">18676739</pub-id></citation></ref>
<ref id="b18-ijms-13-07886"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scaffidi</surname><given-names>C.</given-names></name><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Srinivasan</surname><given-names>A.</given-names></name><name><surname>Friesen</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Tomaselli</surname><given-names>K.J.</given-names></name><name><surname>Debatin</surname><given-names>K.M.</given-names></name><name><surname>Krammer</surname><given-names>P.H.</given-names></name><name><surname>Peter</surname><given-names>M.E.</given-names></name></person-group><article-title>Two cd95 (apo-1/fas) signaling pathways</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><fpage>1675</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.6.1675</pub-id><pub-id pub-id-type="pmid">9501089</pub-id></citation></ref>
<ref id="b19-ijms-13-07886"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A.</given-names></name><name><surname>Dixit</surname><given-names>V.M.</given-names></name></person-group><article-title>Death receptors: Signaling and modulation</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1305</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1126/science.281.5381.1305</pub-id><pub-id pub-id-type="pmid">9721089</pub-id></citation></ref>
<ref id="b20-ijms-13-07886"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>H.</given-names></name><name><surname>Henzel</surname><given-names>W.J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Lutschg</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Apaf-1, a human protein homologous to c. Elegans CED-4, participates in cytochrome c-dependent activation of caspase-3</article-title><source>Cell</source><year>1997</year><volume>90</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80501-2</pub-id><pub-id pub-id-type="pmid">9267021</pub-id></citation></ref>
<ref id="b21-ijms-13-07886"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhagen</surname><given-names>A.M.</given-names></name><name><surname>Ekert</surname><given-names>P.G.</given-names></name><name><surname>Pakusch</surname><given-names>M.</given-names></name><name><surname>Silke</surname><given-names>J.</given-names></name><name><surname>Connolly</surname><given-names>L.M.</given-names></name><name><surname>Reid</surname><given-names>G.E.</given-names></name><name><surname>Moritz</surname><given-names>R.L.</given-names></name><name><surname>Simpson</surname><given-names>R.J.</given-names></name><name><surname>Vaux</surname><given-names>D.L.</given-names></name></person-group><article-title>Identification of diablo, a mammalian protein that promotes apoptosis by binding to and antagonizing iap proteins</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00009-X</pub-id><pub-id pub-id-type="pmid">10929712</pub-id></citation></ref>
<ref id="b22-ijms-13-07886"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elrod</surname><given-names>H.A.</given-names></name><name><surname>Sun</surname><given-names>S.Y.</given-names></name></person-group><article-title>Modulation of death receptors by cancer therapeutic agents</article-title><source>Cancer Biol. Ther</source><year>2008</year><volume>7</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.4161/cbt.7.2.5335</pub-id><pub-id pub-id-type="pmid">18059181</pub-id></citation></ref>
<ref id="b23-ijms-13-07886"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>McDonald</surname><given-names>E.R.</given-names><suffix>3rd</suffix></name><name><surname>Dicker</surname><given-names>D.T.</given-names></name><name><surname>El-Deiry</surname><given-names>W.S.</given-names></name></person-group><article-title>Deficient tumor necrosis factor-related apoptosis-inducing ligand (trail) death receptor transport to the cell surface in human colon cancer cells selected for resistance to trail-induced apoptosis</article-title><source>J. Biol. Chem</source><year>2004</year><volume>279</volume><fpage>35829</fpage><lpage>35839</lpage><pub-id pub-id-type="doi">10.1074/jbc.M405538200</pub-id><pub-id pub-id-type="pmid">15155747</pub-id></citation></ref>
<ref id="b24-ijms-13-07886"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muppidi</surname><given-names>J.R.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name><name><surname>Siegel</surname><given-names>R.M.</given-names></name></person-group><article-title>Life and death decisions: Secondary complexes and lipid rafts in tnf receptor family signal transduction</article-title><source>Immunity</source><year>2004</year><volume>21</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.10.001</pub-id><pub-id pub-id-type="pmid">15485624</pub-id></citation></ref>
<ref id="b25-ijms-13-07886"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Phillips</surname><given-names>D.C.</given-names></name><name><surname>Szekely-Szucs</surname><given-names>K.</given-names></name><name><surname>Elghazi</surname><given-names>L.</given-names></name><name><surname>Desmots</surname><given-names>F.</given-names></name><name><surname>Houghton</surname><given-names>J.A.</given-names></name></person-group><article-title>Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to trail-induced apoptosis through clustering of dr5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>11447</fpage><lpage>11458</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1494</pub-id><pub-id pub-id-type="pmid">16357153</pub-id></citation></ref>
<ref id="b26-ijms-13-07886"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delmas</surname><given-names>D.</given-names></name><name><surname>Rebe</surname><given-names>C.</given-names></name><name><surname>Micheau</surname><given-names>O.</given-names></name><name><surname>Athias</surname><given-names>A.</given-names></name><name><surname>Gambert</surname><given-names>P.</given-names></name><name><surname>Grazide</surname><given-names>S.</given-names></name><name><surname>Laurent</surname><given-names>G.</given-names></name><name><surname>Latruffe</surname><given-names>N.</given-names></name><name><surname>Solary</surname><given-names>E.</given-names></name></person-group><article-title>Redistribution of cd95, dr4 and dr5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>8979</fpage><lpage>8986</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208086</pub-id><pub-id pub-id-type="pmid">15480430</pub-id></citation></ref>
<ref id="b27-ijms-13-07886"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>S.I.</given-names></name><name><surname>Wu</surname><given-names>G.S.</given-names></name><name><surname>Ozoren</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Jen</surname><given-names>J.</given-names></name><name><surname>Sidransky</surname><given-names>D.</given-names></name><name><surname>El-Deiry</surname><given-names>W.S.</given-names></name></person-group><article-title>Rare loss-of-function mutation of a death receptor gene in head and neck cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>3513</fpage><lpage>3518</lpage><pub-id pub-id-type="pmid">9721851</pub-id></citation></ref>
<ref id="b28-ijms-13-07886"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Geelen</surname><given-names>C.M.</given-names></name><name><surname>Pennarun</surname><given-names>B.</given-names></name><name><surname>Ek</surname><given-names>W.B.</given-names></name><name><surname>Le</surname><given-names>P.T.</given-names></name><name><surname>Spierings</surname><given-names>D.C.</given-names></name><name><surname>de Vries</surname><given-names>E.G.</given-names></name><name><surname>de Jong</surname><given-names>S.</given-names></name></person-group><article-title>Downregulation of active caspase 8 as a mechanism of acquired trail resistance in mismatch repair-proficient colon carcinoma cell lines</article-title><source>Int. J. Oncol</source><year>2010</year><volume>37</volume><fpage>1031</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">20811726</pub-id></citation></ref>
<ref id="b29-ijms-13-07886"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Micheau</surname><given-names>O.</given-names></name><name><surname>Thome</surname><given-names>M.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Holler</surname><given-names>N.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name><name><surname>Nicholson</surname><given-names>D.W.</given-names></name><name><surname>Briand</surname><given-names>C.</given-names></name><name><surname>Grutter</surname><given-names>M.G.</given-names></name></person-group><article-title>The long form of flip is an activator of caspase-8 at the fas death-inducing signaling complex</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>45162</fpage><lpage>45171</lpage><pub-id pub-id-type="doi">10.1074/jbc.M206882200</pub-id><pub-id pub-id-type="pmid">12215447</pub-id></citation></ref>
<ref id="b30-ijms-13-07886"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D.W.</given-names></name><name><surname>Xing</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Algeciras-Schimnich</surname><given-names>A.</given-names></name><name><surname>Barnhart</surname><given-names>B.C.</given-names></name><name><surname>Yaish-Ohad</surname><given-names>S.</given-names></name><name><surname>Peter</surname><given-names>M.E.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>C-flip(l) is a dual function regulator for caspase-8 activation and cd95-mediated apoptosis</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>3704</fpage><lpage>3714</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdf356</pub-id><pub-id pub-id-type="pmid">12110583</pub-id></citation></ref>
<ref id="b31-ijms-13-07886"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Geelen</surname><given-names>C.M.</given-names></name><name><surname>de Vries</surname><given-names>E.G.</given-names></name><name><surname>de Jong</surname><given-names>S.</given-names></name></person-group><article-title>Lessons from trail-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy</article-title><source>Drug Resist. Updat</source><year>2004</year><volume>7</volume><fpage>345</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2004.11.002</pub-id><pub-id pub-id-type="pmid">15790545</pub-id></citation></ref>
<ref id="b32-ijms-13-07886"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deveraux</surname><given-names>Q.L.</given-names></name><name><surname>Reed</surname><given-names>J.C.</given-names></name></person-group><article-title>Iap family proteins—Suppressors of apoptosis</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1101/gad.13.3.239</pub-id><pub-id pub-id-type="pmid">9990849</pub-id></citation></ref>
<ref id="b33-ijms-13-07886"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>P.J.</given-names></name><name><surname>Plescia</surname><given-names>J.</given-names></name><name><surname>Clevers</surname><given-names>H.</given-names></name><name><surname>Fearon</surname><given-names>E.R.</given-names></name><name><surname>Altieri</surname><given-names>D.C.</given-names></name></person-group><article-title>Survivin and molecular pathogenesis of colorectal cancer</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13910-4</pub-id><pub-id pub-id-type="pmid">12885482</pub-id></citation></ref>
<ref id="b34-ijms-13-07886"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Fujimoto</surname><given-names>A.</given-names></name><name><surname>Umetani</surname><given-names>N.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Bilchik</surname><given-names>A.</given-names></name><name><surname>Turner</surname><given-names>R.</given-names></name><name><surname>Tran</surname><given-names>A.</given-names></name><name><surname>Kuo</surname><given-names>C.</given-names></name><name><surname>Hoon</surname><given-names>D.S.</given-names></name></person-group><article-title>X-linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/c-met pathway via akt signaling</article-title><source>Clin. Cancer Res</source><year>2005</year><volume>11</volume><fpage>7621</fpage><lpage>7628</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0479</pub-id><pub-id pub-id-type="pmid">16278380</pub-id></citation></ref>
<ref id="b35-ijms-13-07886"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacour</surname><given-names>S.</given-names></name><name><surname>Hammann</surname><given-names>A.</given-names></name><name><surname>Wotawa</surname><given-names>A.</given-names></name><name><surname>Corcos</surname><given-names>L.</given-names></name><name><surname>Solary</surname><given-names>E.</given-names></name><name><surname>Dimanche-Boitrel</surname><given-names>M.T.</given-names></name></person-group><article-title>Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>1645</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">11245478</pub-id></citation></ref>
<ref id="b36-ijms-13-07886"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacour</surname><given-names>S.</given-names></name><name><surname>Micheau</surname><given-names>O.</given-names></name><name><surname>Hammann</surname><given-names>A.</given-names></name><name><surname>Drouineaud</surname><given-names>V.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name><name><surname>Solary</surname><given-names>E.</given-names></name><name><surname>Dimanche-Boitrel</surname><given-names>M.T.</given-names></name></person-group><article-title>Chemotherapy enhances tnf-related apoptosis-inducing ligand disc assembly in ht29 human colon cancer cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>1807</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206127</pub-id><pub-id pub-id-type="pmid">12660816</pub-id></citation></ref>
<ref id="b37-ijms-13-07886"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galligan</surname><given-names>L.</given-names></name><name><surname>Longley</surname><given-names>D.B.</given-names></name><name><surname>McEwan</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>T.R.</given-names></name><name><surname>McLaughlin</surname><given-names>K.</given-names></name><name><surname>Johnston</surname><given-names>P.G.</given-names></name></person-group><article-title>Chemotherapy and trail-mediated colon cancer cell death: The roles of p53, trail receptors, and c-flip</article-title><source>Mol. Cancer Ther</source><year>2005</year><volume>4</volume><fpage>2026</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0262</pub-id><pub-id pub-id-type="pmid">16373718</pub-id></citation></ref>
<ref id="b38-ijms-13-07886"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>R.E.</given-names></name><name><surname>Andrysik</surname><given-names>Z.</given-names></name><name><surname>Paris</surname><given-names>R.</given-names></name><name><surname>Galbraith</surname><given-names>M.D.</given-names></name><name><surname>Espinosa</surname><given-names>J.M.</given-names></name></person-group><article-title>A dr4:Tbid axis drives the p53 apoptotic response by promoting oligomerization of poised bax</article-title><source>EMBO J</source><year>2012</year><volume>31</volume><fpage>1266</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.498</pub-id><pub-id pub-id-type="pmid">22246181</pub-id></citation></ref>
<ref id="b39-ijms-13-07886"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morizot</surname><given-names>A.</given-names></name><name><surname>Merino</surname><given-names>D.</given-names></name><name><surname>Lalaoui</surname><given-names>N.</given-names></name><name><surname>Jacquemin</surname><given-names>G.</given-names></name><name><surname>Granci</surname><given-names>V.</given-names></name><name><surname>Iessi</surname><given-names>E.</given-names></name><name><surname>Lanneau</surname><given-names>D.</given-names></name><name><surname>Bouyer</surname><given-names>F.</given-names></name><name><surname>Solary</surname><given-names>E.</given-names></name><name><surname>Chauffert</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Chemotherapy overcomes trail-r4-mediated trail resistance at the disc level</article-title><source>Cell Death Differ</source><year>2011</year><volume>18</volume><fpage>700</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/cdd.2010.144</pub-id><pub-id pub-id-type="pmid">21072058</pub-id></citation></ref>
<ref id="b40-ijms-13-07886"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Fox</surname><given-names>J.A.</given-names></name><name><surname>Totpal</surname><given-names>K.</given-names></name><name><surname>Aikawa</surname><given-names>M.</given-names></name><name><surname>Dupree</surname><given-names>K.</given-names></name><name><surname>Sinicropi</surname><given-names>D.</given-names></name><name><surname>Lowe</surname><given-names>J.</given-names></name><name><surname>Escandon</surname><given-names>E.</given-names></name></person-group><article-title>Enhanced tumor killing by apo2l/trail and cpt-11 co-treatment is associated with p21 cleavage and differential regulation of apo2l/trail ligand and its receptors</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>3611</fpage><lpage>3619</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205449</pub-id><pub-id pub-id-type="pmid">12032863</pub-id></citation></ref>
<ref id="b41-ijms-13-07886"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouhara</surname><given-names>J.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Nakata</surname><given-names>S.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Ueda</surname><given-names>Y.</given-names></name><name><surname>Yamagishi</surname><given-names>H.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Fenretinide up-regulates dr5/trail-r2 expression via the induction of the transcription factor chop and combined treatment with fenretinide and trail induces synergistic apoptosis in colon cancer cell lines</article-title><source>Int. J. Oncol</source><year>2007</year><volume>30</volume><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">17273769</pub-id></citation></ref>
<ref id="b42-ijms-13-07886"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dolloff</surname><given-names>N.G.</given-names></name><name><surname>Mayes</surname><given-names>P.A.</given-names></name><name><surname>Hart</surname><given-names>L.S.</given-names></name><name><surname>Dicker</surname><given-names>D.T.</given-names></name><name><surname>Humphreys</surname><given-names>R.</given-names></name><name><surname>El-Deiry</surname><given-names>W.S.</given-names></name></person-group><article-title>Off-target lapatinib activity sensitizes colon cancer cells through trail death receptor up-regulation</article-title><source>Sci. Transl. Med</source><year>2011</year><volume>3</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.3001384</pub-id></citation></ref>
<ref id="b43-ijms-13-07886"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Tu</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name></person-group><article-title>Synergistic antitumor effect of trail in combination with sunitinib <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Cancer Lett</source><year>2010</year><volume>293</volume><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2010.01.005</pub-id><pub-id pub-id-type="pmid">20137855</pub-id></citation></ref>
<ref id="b44-ijms-13-07886"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Fajoui</surname><given-names>Z.</given-names></name><name><surname>Toscano</surname><given-names>F.</given-names></name><name><surname>Jacquemin</surname><given-names>G.</given-names></name><name><surname>Abello</surname><given-names>J.</given-names></name><name><surname>Scoazec</surname><given-names>J.Y.</given-names></name><name><surname>Micheau</surname><given-names>O.</given-names></name><name><surname>Saurin</surname><given-names>J.C.</given-names></name></person-group><article-title>Oxaliplatin sensitizes human colon cancer cells to trail through jnk-dependent phosphorylation of bcl-xl</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.04.055</pub-id><pub-id pub-id-type="pmid">21683075</pub-id></citation></ref>
<ref id="b45-ijms-13-07886"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Shiraishi</surname><given-names>T.</given-names></name><name><surname>Nakata</surname><given-names>S.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand</article-title><source>Mol. Cancer Ther</source><year>2006</year><volume>5</volume><fpage>945</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0431</pub-id><pub-id pub-id-type="pmid">16648565</pub-id></citation></ref>
<ref id="b46-ijms-13-07886"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Goda</surname><given-names>A.E.</given-names></name><name><surname>Konishi</surname><given-names>M.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>8918</fpage><lpage>8927</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1120</pub-id><pub-id pub-id-type="pmid">18974136</pub-id></citation></ref>
<ref id="b47-ijms-13-07886"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Takara</surname><given-names>M.</given-names></name><name><surname>Tsuchihashi</surname><given-names>M.</given-names></name><name><surname>Mukai</surname><given-names>N.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer ht29 cells</article-title><source>Environ. Health Prev. Med</source><year>2008</year><volume>13</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1007/s12199-008-0041-1</pub-id><pub-id pub-id-type="pmid">19568915</pub-id></citation></ref>
<ref id="b48-ijms-13-07886"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Konishi</surname><given-names>M.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Goda</surname><given-names>A.E.</given-names></name><name><surname>Taniguchi</surname><given-names>H.</given-names></name><name><surname>Yano</surname><given-names>K.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Kaempferol sensitizes colon cancer cells to trail-induced apoptosis</article-title><source>Biochem. Biophys. Res. Commun</source><year>2008</year><volume>375</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.07.131</pub-id><pub-id pub-id-type="pmid">18680719</pub-id></citation></ref>
<ref id="b49-ijms-13-07886"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Psahoulia</surname><given-names>F.H.</given-names></name><name><surname>Drosopoulos</surname><given-names>K.G.</given-names></name><name><surname>Doubravska</surname><given-names>L.</given-names></name><name><surname>Andera</surname><given-names>L.</given-names></name><name><surname>Pintzas</surname><given-names>A.</given-names></name></person-group><article-title>Quercetin enhances trail-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts</article-title><source>Mol. Cancer Ther</source><year>2007</year><volume>6</volume><fpage>2591</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0001</pub-id><pub-id pub-id-type="pmid">17876056</pub-id></citation></ref>
<ref id="b50-ijms-13-07886"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Polier</surname><given-names>G.</given-names></name><name><surname>Kohler</surname><given-names>R.</given-names></name><name><surname>Giaisi</surname><given-names>M.</given-names></name><name><surname>Krammer</surname><given-names>P.H.</given-names></name><name><surname>Li-Weber</surname><given-names>M.</given-names></name></person-group><article-title>Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (trail) protein resistance of tumors by down-regulation of c-flip protein and up-regulation of trail receptor 2 expression</article-title><source>J. Biol. Chem</source><year>2012</year><volume>287</volume><fpage>641</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.286526</pub-id><pub-id pub-id-type="pmid">22086925</pub-id></citation></ref>
<ref id="b51-ijms-13-07886"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>C.K.</given-names></name><name><surname>Lam</surname><given-names>W.S.</given-names></name><name><surname>Chiu</surname><given-names>L.C.</given-names></name><name><surname>Ooi</surname><given-names>V.E.</given-names></name><name><surname>Sun</surname><given-names>S.S.</given-names></name><name><surname>Wong</surname><given-names>Y.S.</given-names></name></person-group><article-title>A rice bran polyphenol, cycloartenyl ferulate, elicits apoptosis in human colorectal adenocarcinoma sw480 and sensitizes metastatic sw620 cells to trail-induced apoptosis</article-title><source>Biochem. Pharmacol</source><year>2009</year><volume>77</volume><fpage>1487</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2009.02.008</pub-id><pub-id pub-id-type="pmid">19426686</pub-id></citation></ref>
<ref id="b52-ijms-13-07886"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kauntz</surname><given-names>H.</given-names></name><name><surname>Bousserouel</surname><given-names>S.</given-names></name><name><surname>Gosse</surname><given-names>F.</given-names></name><name><surname>Raul</surname><given-names>F.</given-names></name></person-group><article-title>Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells</article-title><source>Apoptosis</source><year>2011</year><volume>16</volume><fpage>1042</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1007/s10495-011-0631-z</pub-id><pub-id pub-id-type="pmid">21779837</pub-id></citation></ref>
<ref id="b53-ijms-13-07886"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>M.K.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Gossypol induces death receptor-5 through activation of the ros-erk-chop pathway and sensitizes colon cancer cells to trail</article-title><source>J. Biol. Chem</source><year>2010</year><volume>285</volume><fpage>35418</fpage><lpage>35427</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.172767</pub-id><pub-id pub-id-type="pmid">20837473</pub-id></citation></ref>
<ref id="b54-ijms-13-07886"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>V.R.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Cardamonin sensitizes tumour cells to trail through ros- and chop-mediated up-regulation of death receptors and down-regulation of survival proteins</article-title><source>Br. J. Pharmacol</source><year>2012</year><volume>165</volume><fpage>741</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01603.x</pub-id><pub-id pub-id-type="pmid">21797841</pub-id></citation></ref>
<ref id="b55-ijms-13-07886"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yodkeeree</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Limtrakul</surname><given-names>P.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Zerumbone enhances trail-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>6581</fpage><lpage>6589</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1161</pub-id><pub-id pub-id-type="pmid">19654295</pub-id></citation></ref>
<ref id="b56-ijms-13-07886"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.C.</given-names></name><name><surname>Reuter</surname><given-names>S.</given-names></name><name><surname>Phromnoi</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>B.</given-names></name><name><surname>Hema</surname><given-names>P.S.</given-names></name><name><surname>Nair</surname><given-names>M.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Nimbolide sensitizes human colon cancer cells to trail through reactive oxygen species- and erk-dependent up-regulation of death receptors, p53, and bax</article-title><source>J. Biol. Chem</source><year>2011</year><volume>286</volume><fpage>1134</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.191379</pub-id><pub-id pub-id-type="pmid">21078664</pub-id></citation></ref>
<ref id="b57-ijms-13-07886"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Maoka</surname><given-names>T.</given-names></name><name><surname>Das</surname><given-names>S.K.</given-names></name><name><surname>Kanazawa</surname><given-names>K.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Satomi</surname><given-names>Y.</given-names></name><name><surname>Nishino</surname><given-names>H.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand</article-title><source>Mol. Cancer Res</source><year>2007</year><volume>5</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0045</pub-id><pub-id pub-id-type="pmid">17579120</pub-id></citation></ref>
<ref id="b58-ijms-13-07886"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kannappan</surname><given-names>R.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Yadav</surname><given-names>V.R.</given-names></name><name><surname>Reuter</surname><given-names>S.</given-names></name><name><surname>Chaturvedi</surname><given-names>M.M.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Gamma-tocotrienol promotes trail-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors</article-title><source>Mol. Cancer Ther</source><year>2010</year><volume>9</volume><fpage>2196</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0277</pub-id><pub-id pub-id-type="pmid">20682650</pub-id></citation></ref>
<ref id="b59-ijms-13-07886"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Pandey</surname><given-names>M.K.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Garcinol potentiates trail-induced apoptosis through modulation of death receptors and antiapoptotic proteins</article-title><source>Mol. Cancer Ther</source><year>2010</year><volume>9</volume><fpage>856</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-1113</pub-id><pub-id pub-id-type="pmid">20371723</pub-id></citation></ref>
<ref id="b60-ijms-13-07886"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>Y.Z.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>N.M.</given-names></name><name><surname>He</surname><given-names>Q.J.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name></person-group><article-title>Enhanced anti-tumor activity by the combination of trail/apo-2l and combretastatin a-4 against human colon cancer cells via induction of apoptosis <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Cancer Lett</source><year>2011</year><volume>302</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2010.12.001</pub-id><pub-id pub-id-type="pmid">21236562</pub-id></citation></ref>
<ref id="b61-ijms-13-07886"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raviv</surname><given-names>Z.</given-names></name><name><surname>Zilberberg</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name><name><surname>Reischer-Pelech</surname><given-names>D.</given-names></name><name><surname>Horrix</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>M.R.</given-names></name><name><surname>Rosin-Arbesfeld</surname><given-names>R.</given-names></name><name><surname>Flescher</surname><given-names>E.</given-names></name></person-group><article-title>Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards trail-induced cytotoxicity</article-title><source>Br. J. Pharmacol</source><year>2011</year><volume>164</volume><fpage>1433</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01419.x</pub-id><pub-id pub-id-type="pmid">21486277</pub-id></citation></ref>
<ref id="b62-ijms-13-07886"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaculova</surname><given-names>A.</given-names></name><name><surname>Hofmanova</surname><given-names>J.</given-names></name><name><surname>Andera</surname><given-names>L.</given-names></name><name><surname>Kozubik</surname><given-names>A.</given-names></name></person-group><article-title>Trail and docosahexaenoic acid cooperate to induce ht-29 colon cancer cell death</article-title><source>Cancer Lett</source><year>2005</year><volume>229</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.12.016</pub-id><pub-id pub-id-type="pmid">16157217</pub-id></citation></ref>
<ref id="b63-ijms-13-07886"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lepage</surname><given-names>C.</given-names></name><name><surname>Leger</surname><given-names>D.Y.</given-names></name><name><surname>Bertrand</surname><given-names>J.</given-names></name><name><surname>Martin</surname><given-names>F.</given-names></name><name><surname>Beneytout</surname><given-names>J.L.</given-names></name><name><surname>Liagre</surname><given-names>B.</given-names></name></person-group><article-title>Diosgenin induces death receptor-5 through activation of p38 pathway and promotes trail-induced apoptosis in colon cancer cells</article-title><source>Cancer Lett</source><year>2011</year><volume>301</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2010.12.003</pub-id><pub-id pub-id-type="pmid">21195543</pub-id></citation></ref>
<ref id="b64-ijms-13-07886"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Alt</surname><given-names>E.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Lynch</surname><given-names>P.M.</given-names></name><name><surname>Moyer</surname><given-names>M.P.</given-names></name><name><surname>Wen</surname><given-names>X.F.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Chemoprevention of colorectal cancer by targeting apc-deficient cells for apoptosis</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>1058</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1038/nature08871</pub-id><pub-id pub-id-type="pmid">20348907</pub-id></citation></ref>
<ref id="b65-ijms-13-07886"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Sheikh</surname><given-names>M.S.</given-names></name></person-group><article-title>Proteasome inhibitor mg132 upregulates death receptor 5 and cooperates with apo2l/trail to induce apoptosis in bax-proficient and -deficient cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>2554</fpage><lpage>2558</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207351</pub-id><pub-id pub-id-type="pmid">14691451</pub-id></citation></ref>
<ref id="b66-ijms-13-07886"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>T.R.</given-names></name><name><surname>Stone</surname><given-names>K.</given-names></name><name><surname>Nikrad</surname><given-names>M.</given-names></name><name><surname>Yeh</surname><given-names>T.</given-names></name><name><surname>Zong</surname><given-names>W.X.</given-names></name><name><surname>Thompson</surname><given-names>C.B.</given-names></name><name><surname>Nesterov</surname><given-names>A.</given-names></name><name><surname>Kraft</surname><given-names>A.S.</given-names></name></person-group><article-title>The proteasome inhibitor ps-341 overcomes trail resistance in bax and caspase 9-negative or bcl-xl overexpressing cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>4953</fpage><lpage>4963</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206656</pub-id><pub-id pub-id-type="pmid">12902978</pub-id></citation></ref>
<ref id="b67-ijms-13-07886"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>R.Y.</given-names></name><name><surname>Chi</surname><given-names>K.H.</given-names></name><name><surname>Huang</surname><given-names>D.Y.</given-names></name><name><surname>Tai</surname><given-names>M.H.</given-names></name><name><surname>Lin</surname><given-names>W.W.</given-names></name></person-group><article-title>15-deoxy-delta12,14-prostaglandin j2 up-regulates death receptor 5 gene expression in hct116 cells: Involvement of reactive oxygen species and c/ebp homologous transcription factor gene transcription</article-title><source>Mol. Cancer Ther</source><year>2008</year><volume>7</volume><fpage>3429</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0498</pub-id><pub-id pub-id-type="pmid">18852146</pub-id></citation></ref>
<ref id="b68-ijms-13-07886"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Yadav</surname><given-names>V.R.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Ros and chop are critical for dibenzylideneacetone to sensitize tumor cells to trail through induction of death receptors and downregulation of cell survival proteins</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3121</pub-id><pub-id pub-id-type="pmid">21127198</pub-id></citation></ref>
<ref id="b69-ijms-13-07886"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stolfi</surname><given-names>C.</given-names></name><name><surname>Caruso</surname><given-names>R.</given-names></name><name><surname>Franze</surname><given-names>E.</given-names></name><name><surname>Rizzo</surname><given-names>A.</given-names></name><name><surname>Rotondi</surname><given-names>A.</given-names></name><name><surname>Monteleone</surname><given-names>I.</given-names></name><name><surname>Fantini</surname><given-names>M.C.</given-names></name><name><surname>Pallone</surname><given-names>F.</given-names></name><name><surname>Monteleone</surname><given-names>G.</given-names></name></person-group><article-title>2-methoxy-5-amino-n-hydroxybenzamide sensitizes colon cancer cells to trail-induced apoptosis by regulating death receptor 5 and survivin expression</article-title><source>Mol. Cancer Ther</source><year>2011</year><volume>10</volume><fpage>1969</fpage><lpage>1981</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0316</pub-id><pub-id pub-id-type="pmid">21817114</pub-id></citation></ref>
<ref id="b70-ijms-13-07886"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goda</surname><given-names>A.E.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Horinaka</surname><given-names>M.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Shiraishi</surname><given-names>T.</given-names></name><name><surname>Wakada</surname><given-names>M.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><article-title>Mechanisms of enhancement of trail tumoricidal activity against human cancer cells of different origin by dipyridamole</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>3435</fpage><lpage>3445</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1211008</pub-id><pub-id pub-id-type="pmid">18193086</pub-id></citation></ref>
<ref id="b71-ijms-13-07886"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>T.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Kanamori</surname><given-names>M.</given-names></name><name><surname>Tabuchi</surname><given-names>Y.</given-names></name><name><surname>Ogawa</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>Q.L.</given-names></name><name><surname>Ahmed</surname><given-names>K.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Seki</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma hos cells and human colon cancer hct116 cells</article-title><source>Cancer Lett</source><year>2010</year><volume>287</volume><fpage>98</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.06.002</pub-id><pub-id pub-id-type="pmid">19577358</pub-id></citation></ref>
<ref id="b72-ijms-13-07886"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>R.Y.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>T.Y.</given-names></name><name><surname>Huang</surname><given-names>D.Y.</given-names></name><name><surname>Lin</surname><given-names>W.W.</given-names></name></person-group><article-title>5-aminoimidazole-4-carboxamide riboside sensitizes trail- and tnf{alpha}-induced cytotoxicity in colon cancer cells through amp-activated protein kinase signaling</article-title><source>Mol. Cancer Ther</source><year>2007</year><volume>6</volume><fpage>1562</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0800</pub-id><pub-id pub-id-type="pmid">17513605</pub-id></citation></ref>
<ref id="b73-ijms-13-07886"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tillman</surname><given-names>D.M.</given-names></name><name><surname>Izeradjene</surname><given-names>K.</given-names></name><name><surname>Szucs</surname><given-names>K.S.</given-names></name><name><surname>Douglas</surname><given-names>L.</given-names></name><name><surname>Houghton</surname><given-names>J.A.</given-names></name></person-group><article-title>Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase c</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>5118</fpage><lpage>5125</lpage><pub-id pub-id-type="pmid">12941843</pub-id></citation></ref>
<ref id="b74-ijms-13-07886"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasilevskaya</surname><given-names>I.A.</given-names></name><name><surname>O’Dwyer</surname><given-names>P.J.</given-names></name></person-group><article-title>17-allylamino-17-demethoxygeldanamycin overcomes trail resistance in colon cancer cell lines</article-title><source>Biochem. Pharmacol</source><year>2005</year><volume>70</volume><fpage>580</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.05.018</pub-id><pub-id pub-id-type="pmid">15993848</pub-id></citation></ref>
<ref id="b75-ijms-13-07886"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toscano</surname><given-names>F.</given-names></name><name><surname>Fajoui</surname><given-names>Z.E.</given-names></name><name><surname>Gay</surname><given-names>F.</given-names></name><name><surname>Lalaoui</surname><given-names>N.</given-names></name><name><surname>Parmentier</surname><given-names>B.</given-names></name><name><surname>Chayvialle</surname><given-names>J.A.</given-names></name><name><surname>Scoazec</surname><given-names>J.Y.</given-names></name><name><surname>Micheau</surname><given-names>O.</given-names></name><name><surname>Abello</surname><given-names>J.</given-names></name><name><surname>Saurin</surname><given-names>J.C.</given-names></name></person-group><article-title>P53-mediated upregulation of dcr1 impairs oxaliplatin/trail-induced synergistic anti-tumour potential in colon cancer cells</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>4161</fpage><lpage>4171</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.52</pub-id><pub-id pub-id-type="pmid">18345033</pub-id></citation></ref>
<ref id="b76-ijms-13-07886"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.X.</given-names></name><name><surname>Ogawa</surname><given-names>O.</given-names></name><name><surname>Kakehi</surname><given-names>Y.</given-names></name></person-group><article-title>Trail and chemotherapeutic drugs in cancer therapy</article-title><source>Vitam. Horm</source><year>2004</year><volume>67</volume><fpage>365</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">15110186</pub-id></citation></ref>
<ref id="b77-ijms-13-07886"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>D.</given-names></name></person-group><article-title>Natural products and their role in cancer therapy</article-title><source>Med. Oncol</source><year>2011</year><volume>28</volume><fpage>888</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s12032-010-9528-x</pub-id><pub-id pub-id-type="pmid">20414819</pub-id></citation></ref>
<ref id="b78-ijms-13-07886"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>C.L.</given-names></name><name><surname>Bauer</surname><given-names>J.A.</given-names></name><name><surname>Wolter</surname><given-names>K.G.</given-names></name><name><surname>Ubell</surname><given-names>M.L.</given-names></name><name><surname>Narayan</surname><given-names>A.</given-names></name><name><surname>O’Connell</surname><given-names>K.M.</given-names></name><name><surname>Fisher</surname><given-names>S.G.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>M.</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> effects of the bh3 mimetic, (−)-gossypol, on head and neck squamous cell carcinoma cells</article-title><source>Clin. Cancer Res</source><year>2004</year><volume>10</volume><fpage>7757</fpage><lpage>7763</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0551</pub-id><pub-id pub-id-type="pmid">15570010</pub-id></citation></ref>
<ref id="b79-ijms-13-07886"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabi</surname><given-names>T.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group><article-title>Terpenoids and breast cancer chemoprevention</article-title><source>Breast Cancer Res. Treat</source><year>2009</year><volume>115</volume><fpage>223</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1007/s10549-008-0118-y</pub-id><pub-id pub-id-type="pmid">18636327</pub-id></citation></ref>
<ref id="b80-ijms-13-07886"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thoppil</surname><given-names>R.J.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group><article-title>Terpenoids as potential chemopreventive and therapeutic agents in liver cancer</article-title><source>World J. Hepatol</source><year>2011</year><volume>3</volume><fpage>228</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.4254/wjh.v3.i9.228</pub-id><pub-id pub-id-type="pmid">21969877</pub-id></citation></ref>
<ref id="b81-ijms-13-07886"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirana</surname><given-names>C.</given-names></name><name><surname>McIntosh</surname><given-names>G.H.</given-names></name><name><surname>Record</surname><given-names>I.R.</given-names></name><name><surname>Jones</surname><given-names>G.P.</given-names></name></person-group><article-title>Antitumor activity of extract of zingiber aromaticum and its bioactive sesquiterpenoid zerumbone</article-title><source>Nutr. Cancer</source><year>2003</year><volume>45</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1207/S15327914NC4502_12</pub-id><pub-id pub-id-type="pmid">12881017</pub-id></citation></ref>
<ref id="b82-ijms-13-07886"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sterz</surname><given-names>J.</given-names></name><name><surname>von Metzler</surname><given-names>I.</given-names></name><name><surname>Hahne</surname><given-names>J.C.</given-names></name><name><surname>Lamottke</surname><given-names>B.</given-names></name><name><surname>Rademacher</surname><given-names>J.</given-names></name><name><surname>Heider</surname><given-names>U.</given-names></name><name><surname>Terpos</surname><given-names>E.</given-names></name><name><surname>Sezer</surname><given-names>O.</given-names></name></person-group><article-title>The potential of proteasome inhibitors in cancer therapy</article-title><source>Expert Opin. Investig. Drugs</source><year>2008</year><volume>17</volume><fpage>879</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1517/13543784.17.6.879</pub-id><pub-id pub-id-type="pmid">18491989</pub-id></citation></ref>
<ref id="b83-ijms-13-07886"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>M.</given-names></name><name><surname>Kaufman</surname><given-names>R.J.</given-names></name></person-group><article-title>Er stress and the unfolded protein response</article-title><source>Mutat. Res</source><year>2005</year><volume>569</volume><fpage>29</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2004.06.056</pub-id><pub-id pub-id-type="pmid">15603751</pub-id></citation></ref>
<ref id="b84-ijms-13-07886"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin-Perez</surname><given-names>R.</given-names></name><name><surname>Niwa</surname><given-names>M.</given-names></name><name><surname>Lopez-Rivas</surname><given-names>A.</given-names></name></person-group><article-title>Er stress sensitizes cells to trail through down-regulation of flip and mcl-1 and perk-dependent up-regulation of trail-r2</article-title><source>Apoptosis</source><year>2012</year><volume>17</volume><fpage>349</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1007/s10495-011-0673-2</pub-id><pub-id pub-id-type="pmid">22072062</pub-id></citation></ref>
<ref id="b85-ijms-13-07886"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stolfi</surname><given-names>C.</given-names></name><name><surname>Sarra</surname><given-names>M.</given-names></name><name><surname>Caruso</surname><given-names>R.</given-names></name><name><surname>Fantini</surname><given-names>M.C.</given-names></name><name><surname>Fina</surname><given-names>D.</given-names></name><name><surname>Pellegrini</surname><given-names>R.</given-names></name><name><surname>Palmieri</surname><given-names>G.</given-names></name><name><surname>Macdonald</surname><given-names>T.T.</given-names></name><name><surname>Pallone</surname><given-names>F.</given-names></name><name><surname>Monteleone</surname><given-names>G.</given-names></name></person-group><article-title>Inhibition of colon carcinogenesis by 2-methoxy-5-amino-n-hydroxybenzamide, a novel derivative of mesalamine</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.08.062</pub-id><pub-id pub-id-type="pmid">19737563</pub-id></citation></ref>
<ref id="b86-ijms-13-07886"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>H.M.</given-names></name></person-group><article-title>Targeting p53 as a therapeutic strategy in sensitizing trail-induced apoptosis in cancer cells</article-title><source>Cancer Lett</source><year>2012</year><volume>314</volume><fpage>8</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.09.040</pub-id><pub-id pub-id-type="pmid">22030255</pub-id></citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figure and Table</title>
<fig id="f1-ijms-13-07886" position="float">
<label>Figure 1</label>
<caption>
<p>TRAIL signaling pathway and mechanisms of TRAIL resistance. Binding of TRAIL to DR4 or DR5 leads to activation of caspase-8 through FADD. Activated caspase-8 can directly activate effector caspase-3, -6, and -7 via the extrinsic pathway or cleave Bid and activate the intrinsic mitochondria-mediated pathway. Initiation of the latter pathway leads to activation of effector caspases through caspase-9. Activation of caspase-3, -6, and -7 leads to apoptosis. TRAIL resistance can occur at several levels. At the outer membrane, TRAIL sensitivity can be reduced by DcR1 and/or DcR2 over-expression as well as by defective expression/function of DR4 and/or DR5 (1). At the DISC, down-regulation, degradation or inactivation of the initiator caspase-8 and/or increased expression of c-FLIP can lead to TRAIL resistance (2). At the mitochondria, defects in pro-apoptotic molecules (e.g., Bid, Bax, Bak, PUMA, Bim) and/or up-regulation of proteins able to prevent cytochrome c and Smac/DIABLO release (e.g., Bcl-2, Bcl-xL and Mcl-1) also interfere with TRAIL signaling (3). Finally, members of the IAP family prevent the activation of both caspase-9 and caspase-3, -6 and -7 (4). →indicates activation, ⊥ indicates inhibition.</p></caption>
<graphic xlink:href="ijms-13-07886f1.gif"/></fig>
<table-wrap id="t1-ijms-13-07886" position="float">
<label>Table 1</label>
<caption>
<p>Mechanism(s) of action of TRAIL-sensitizing agents in CRC cells.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Therapeutics</th>
<th align="left" valign="bottom">Cells</th>
<th align="left" valign="bottom">Mechanism(s)</th>
<th align="center" valign="bottom">Reference</th></tr></thead>
<tbody>
<tr>
<td colspan="4" align="left" valign="top"><bold><italic>Chemotherapeutics</italic></bold></td></tr>
<tr>
<td align="left" valign="top">Cisplatin</td>
<td align="left" valign="top">HT-29, SW480</td>
<td align="left" valign="top">Caspase-8 activation, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b35-ijms-13-07886">35</xref>,<xref ref-type="bibr" rid="b36-ijms-13-07886">36</xref>]</td></tr>
<tr>
<td align="left" valign="top">5-FU</td>
<td align="left" valign="top">HCT-116, HT-29</td>
<td align="left" valign="top">Caspase-8 activation, ↓c-FLIP, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b35-ijms-13-07886">35</xref>–<xref ref-type="bibr" rid="b38-ijms-13-07886">38</xref>]</td></tr>
<tr>
<td align="left" valign="top">VP16</td>
<td align="left" valign="top">HCT-116, SW480</td>
<td align="left" valign="top">Caspase-8 activation</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b39-ijms-13-07886">39</xref>]</td></tr>
<tr>
<td align="left" valign="top">Doxorubicin</td>
<td align="left" valign="top">HT-29, SW480</td>
<td align="left" valign="top">Caspase-8 activation, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b35-ijms-13-07886">35</xref>,<xref ref-type="bibr" rid="b36-ijms-13-07886">36</xref>]</td></tr>
<tr>
<td align="left" valign="top">DuP-697</td>
<td align="left" valign="top">HT-29</td>
<td align="left" valign="top">DR5 and DISC component redistribution in lipid rafts</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b25-ijms-13-07886">25</xref>]</td></tr>
<tr>
<td align="left" valign="top">CPT-11</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR4, ↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b40-ijms-13-07886">40</xref>]</td></tr>
<tr>
<td align="left" valign="top">Fenretinide</td>
<td align="left" valign="top">HT-29, SW480</td>
<td align="left" valign="top">↑DR5, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b41-ijms-13-07886">41</xref>]</td></tr>
<tr>
<td align="left" valign="top">Lapatinib</td>
<td align="left" valign="top">HCT-116, SW480, SW620, DLD-1, HT-29</td>
<td align="left" valign="top">↑DR4, ↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b42-ijms-13-07886">42</xref>]</td></tr>
<tr>
<td align="left" valign="top">Sunitinib</td>
<td align="left" valign="top">SW620</td>
<td align="left" valign="top">↓c-FLIP, ↓Mcl-1, ↓XIAP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b43-ijms-13-07886">43</xref>]</td></tr>
<tr>
<td align="left" valign="top">Oxaliplatin</td>
<td align="left" valign="top">HT-29, V9P</td>
<td align="left" valign="top">↓Bcl-xL anti-apoptotic activity</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b44-ijms-13-07886">44</xref>]</td></tr>
<tr>
<td colspan="4" align="left" valign="top"><bold><italic>Natural products</italic></bold></td></tr>
<tr>
<td align="left" valign="top">Apigenin</td>
<td align="left" valign="top">DLD1</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b45-ijms-13-07886">45</xref>]</td></tr>
<tr>
<td align="left" valign="top">Baicalein</td>
<td align="left" valign="top">SW480</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b46-ijms-13-07886">46</xref>]</td></tr>
<tr>
<td align="left" valign="top">Isoliquiritigenin</td>
<td align="left" valign="top">HT-29</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b47-ijms-13-07886">47</xref>]</td></tr>
<tr>
<td align="left" valign="top">Kaempferol</td>
<td align="left" valign="top">SW480</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b48-ijms-13-07886">48</xref>]</td></tr>
<tr>
<td align="left" valign="top">Quercetin</td>
<td align="left" valign="top">HT-29, SW620, CACO-2</td>
<td align="left" valign="top">DR4 and DR5 redistribution in lipid rafts</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b49-ijms-13-07886">49</xref>]</td></tr>
<tr>
<td align="left" valign="top">Wogonin</td>
<td align="left" valign="top">HT-29</td>
<td align="left" valign="top">↑DR5, ↓c-FLIP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b50-ijms-13-07886">50</xref>]</td></tr>
<tr>
<td align="left" valign="top">Cycloartenyl ferulate</td>
<td align="left" valign="top">SW480, SW620</td>
<td align="left" valign="top">↑DR4, ↑DR5, Bid cleavage, Bcl-2, Bax</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b51-ijms-13-07886">51</xref>]</td></tr>
<tr>
<td align="left" valign="top">Silibinin</td>
<td align="left" valign="top">SW480, SW620</td>
<td align="left" valign="top">↑DR5, ↓Mcl-1, ↓XIAP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b52-ijms-13-07886">52</xref>]</td></tr>
<tr>
<td align="left" valign="top">Gossypol</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR5, ↓Bcl-2, ↓Bcl-xL, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b53-ijms-13-07886">53</xref>]</td></tr>
<tr>
<td align="left" valign="top">Cardamonin</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR4, ↑DR5, ↓DcR1, ↑Bax, ↓Bcl-2, ↓c-IAP1</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b54-ijms-13-07886">54</xref>]</td></tr>
<tr>
<td align="left" valign="top">Zerumbone</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR4, ↑DR5, ↓c-FLIP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b55-ijms-13-07886">55</xref>]</td></tr>
<tr>
<td align="left" valign="top">Nimbolide</td>
<td align="left" valign="top">HCT-116, HT-29</td>
<td align="left" valign="top">↑DR4, ↑DR5, ↓c-FLIP, ↑Bax, ↓Bcl-2, ↓Bcl-xL, ↓c-IAP1, ↓c-IAP2, ↓survivin, ↓XIAP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b56-ijms-13-07886">56</xref>]</td></tr>
<tr>
<td align="left" valign="top">Halocynthiaxanthin</td>
<td align="left" valign="top">DLD1, HT-29</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b57-ijms-13-07886">57</xref>]</td></tr>
<tr>
<td align="left" valign="top">γ-T3</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR4, ↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b58-ijms-13-07886">58</xref>]</td></tr>
<tr>
<td align="left" valign="top">Garcinol</td>
<td align="left" valign="top">HCT-116, HT-29</td>
<td align="left" valign="top">↑DR4, ↑DR5, Bid cleavage ↓c-FLIP, ↓Bcl-2, ↓XIAP, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b59-ijms-13-07886">59</xref>]</td></tr>
<tr>
<td align="left" valign="top">Combretastatin A-4</td>
<td align="left" valign="top">HCT-116, SW620</td>
<td align="left" valign="top">↓c-FLIP, ↓Mcl-1</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b60-ijms-13-07886">60</xref>]</td></tr>
<tr>
<td align="left" valign="top">Methyl jasmonate</td>
<td align="left" valign="top">HCT-116, SW480</td>
<td align="left" valign="top">Bid cleavage, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b61-ijms-13-07886">61</xref>]</td></tr>
<tr>
<td align="left" valign="top">DHA</td>
<td align="left" valign="top">HT-29</td>
<td align="left" valign="top">Caspase-8 activation, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b62-ijms-13-07886">62</xref>]</td></tr>
<tr>
<td align="left" valign="top">Diosgenin</td>
<td align="left" valign="top">HT-29</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b63-ijms-13-07886">63</xref>]</td></tr>
<tr>
<td align="left" valign="top">RAc</td>
<td align="left" valign="top">APC-deleted NCM356</td>
<td align="left" valign="top">↑DR4, ↑DR5, ↓DcR1, ↓DcR2</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b64-ijms-13-07886">64</xref>]</td></tr>
<tr>
<td colspan="4" align="left" valign="top"><bold><italic>Other agents</italic></bold></td></tr>
<tr>
<td align="left" valign="top">MG-132</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b65-ijms-13-07886">65</xref>]</td></tr>
<tr>
<td align="left" valign="top">PS-341</td>
<td align="left" valign="top">HCT-116, HC-4</td>
<td align="left" valign="top">↑DR4, ↑DR5, caspase-8 activation, Bid cleavage</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b66-ijms-13-07886">66</xref>]</td></tr>
<tr>
<td align="left" valign="top">15dPGJ<sub>2</sub></td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR5</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b67-ijms-13-07886">67</xref>]</td></tr>
<tr>
<td align="left" valign="top">DBA</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR4, ↑DR5, ↓DcR2, ↓Bcl-2, ↓XIAP, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b68-ijms-13-07886">68</xref>]</td></tr>
<tr>
<td align="left" valign="top">2–14</td>
<td align="left" valign="top">DLD1, HT-29</td>
<td align="left" valign="top">↑DR5, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b69-ijms-13-07886">69</xref>]</td></tr>
<tr>
<td align="left" valign="top">Dipyridamole</td>
<td align="left" valign="top">SW480</td>
<td align="left" valign="top">↑DR5, ↓survivin</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b70-ijms-13-07886">70</xref>]</td></tr>
<tr>
<td align="left" valign="top">Nutlin-3</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">↑DR5, ↓Bcl-2, ↓XIAP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b71-ijms-13-07886">71</xref>]</td></tr>
<tr>
<td align="left" valign="top">AICAR</td>
<td align="left" valign="top">HCT-116</td>
<td align="left" valign="top">Bid cleavage, ↓Bcl-2</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b72-ijms-13-07886">72</xref>]</td></tr>
<tr>
<td align="left" valign="top">Rottlerin</td>
<td align="left" valign="top">HT-29, RKO</td>
<td align="left" valign="top">Cytochrome c and Smac/DIABLO release, ↓XIAP<break/>↓c-IAP1</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b73-ijms-13-07886">73</xref>]</td></tr>
<tr>
<td align="left" valign="top">17-AAG</td>
<td align="left" valign="top">HT-29, RKO</td>
<td align="left" valign="top">Bid cleavage, ↓XIAP</td>
<td align="center" valign="top">[<xref ref-type="bibr" rid="b74-ijms-13-07886">74</xref>]</td></tr></tbody></table></table-wrap></sec></back></article>
